Patents by Inventor Ole Petter Veiby

Ole Petter Veiby has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions, kits, and methods for identification, assessment, prevention and therapy of breast and ovarian cancer
    Patent number: 10533227
    Abstract: The invention relates to newly discovered nucleic acid molecules and proteins associated with breast or ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast or ovarian cancers are provided.
    Type: Grant
    Filed: November 3, 2015
    Date of Patent: January 14, 2020
    Assignees: Millennium Pharmaceuticals, Inc., Board of Regents, University of Texas System
    Inventors: Ole Petter Veiby, Robert C. Bast, Gordon B. Mills, Gabriel N. Hortobagyi
  • Combination of aurora kinase inhibitors and anti-CD30 antibodies
    Patent number: 10335494
    Abstract: The present invention relates to methods for the treatment of cancers. In particular, the invention provides methods for treatment of cancer by administering an Aurora kinase inhibitor in combination with an anti-CD30 antibody. The combined administration of the Aurora kinase inhibitor and anti-CD30 antibody can be simultaneous, separate, sequential or consecutive.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: July 2, 2019
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventor: Ole Petter Veiby
  • GCC-TARGETED ANTIBODY-DRUG CONJUGATES
    Publication number: 20190038762
    Abstract: This invention relates to antibody-drug conjugates capable of delivering cytotoxic compounds to cancers expressing the guanylyl cyclase C (GCC) transmembrane cell surface receptor.
    Type: Application
    Filed: February 3, 2017
    Publication date: February 7, 2019
    Applicants: MILLENNIUM PHARMACEUTICALS, INC., IMMUNOGEN, INC.
    Inventors: Ole Petter VEIBY, Ravi V. J. CHARI, John M. LAMBERT, Katharine C. LAI, Robert W. HERBST, Scott A. HILDERBRAND
  • COMBINATION THERAPIES OF HER2-TARGETED ANTIBODY-DRUG CONJUGATES
    Publication number: 20180271996
    Abstract: Disclose herein are combinations comprising HER2-targeted antibody-drug conjugates and immune checkpoint inhibitors and methods of using such combinations in a variety of therapeutic, diagnostic, and prophylactic indications.
    Type: Application
    Filed: February 27, 2018
    Publication date: September 27, 2018
    Applicants: Mersana Therapeutics, Inc., Millennium Pharmaceuticals Inc.
    Inventors: Natalya D. BODYAK, Donald A. BERGSTROM, Marc HYER, Timothy B. LOWINGER, Marina PROTOPOPOVA, Ole Petter VEIBY, Aleksandr V. YURKOVETSKIY, Qing Xiu ZHANG
  • Antibodies that bind OV064 and methods of use therefor
    Patent number: 9926378
    Abstract: Antibodies and antigen-binding fragments of antibodies that bind OV064 are disclosed. The antibodies bind an extracellular domain of OV064. Some of the antibodies and antigen-binding fragments bind an epitope on OV064 sufficient to induce internalization. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: March 27, 2018
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Ole Petter Veiby, John S. Babcook
  • COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF BREAST AND OVARIAN CANCER
    Publication number: 20160326591
    Abstract: The invention relates to newly discovered nucleic acid molecules and proteins associated with breast or ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast or ovarian cancers are provided.
    Type: Application
    Filed: November 3, 2015
    Publication date: November 10, 2016
    Inventors: Ole Petter Veiby, Robert C. Bast, Gordon B. Mills, Gabriel N. Hortobagyi
  • ANTIBODIES THAT BIND OV064 AND METHODS OF USE THEREFOR
    Publication number: 20160319030
    Abstract: Antibodies and antigen-binding fragments of antibodies that bind OV064 are disclosed. The antibodies bind an extracellular domain of OV064. Some of the antibodies and antigen-binding fragments bind an epitope on OV064 sufficient to induce internalization. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.
    Type: Application
    Filed: July 21, 2016
    Publication date: November 3, 2016
    Applicant: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Ole Petter Veiby, John S. Babcook
  • COMBINATION OF AURORA KINASE INHIBITORS AND ANTI-CD30 ANTIBODIES
    Publication number: 20160303249
    Abstract: The present invention relates to methods for the treatment of cancers. In particular, the invention provides methods for treatment of cancer by administering an Aurora kinase inhibitor in combination with an anti-CD30 antibody. The combined administration of the Aurora kinase inhibitor and anti-CD30 antibody can be simultaneous, separate, sequential or consecutive.
    Type: Application
    Filed: December 8, 2014
    Publication date: October 20, 2016
    Inventor: Ole Petter Veiby
  • Antibodies that bind OV064 and methods of use therefor
    Patent number: 9421277
    Abstract: Antibodies and antigen-binding fragments of antibodies that bind OV064 are disclosed. The antibodies bind an extracellular domain of OV064. Some of the antibodies and antigen-binding fragments bind an epitope on OV064 sufficient to induce internalization. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.
    Type: Grant
    Filed: April 9, 2014
    Date of Patent: August 23, 2016
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Ole Petter Veiby, John S. Babcook
  • ADMINISTRATION OF AN ANTI-GCC ANTIBODY-DRUG CONJUGATE AND A DNA DAMAGING AGENT IN THE TREATMENT OF CANCER
    Publication number: 20140356383
    Abstract: The present invention relates to methods for the treatment of gastrointestinal cancers. In particular, the invention provides methods for treatment of a gastrointestinal cancer by administering an immunoconjugate comprising an anti-GCC antibody molecule in combination with a DNA damaging agent.
    Type: Application
    Filed: February 27, 2014
    Publication date: December 4, 2014
    Inventor: Ole Petter Veiby
  • ANTIBODIES THAT BIND OV064 AND METHODS OF USE THEREFOR
    Publication number: 20140328751
    Abstract: Antibodies and antigen-binding fragments of antibodies that bind OV064 are disclosed. The antibodies bind an extracellular domain of OV064. Some of the antibodies and antigen-binding fragments bind an epitope on OV064 sufficient to induce internalization. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.
    Type: Application
    Filed: April 9, 2014
    Publication date: November 6, 2014
    Applicant: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Ole Petter Veiby, John S. Babcook
  • Antibodies that bind OV064 and methods of use therefor
    Patent number: 8759490
    Abstract: Antibodies and antigen-binding fragments of antibodies that bind OV064 are disclosed. The antibodies bind an extracellular domain of OV064. Some of the antibodies and antigen-binding fragments bind an epitope on OV064 sufficient to induce internalization. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.
    Type: Grant
    Filed: November 1, 2012
    Date of Patent: June 24, 2014
    Assignee: Millennium Pharamaceuticals, Inc.
    Inventors: Ole Petter Veiby, John S. Babcook
  • CCR1 INHIBITORS USEFUL FOR THE TREAMENT OF MULTIPLE MYELOMA AND OTHER DISORDERS
    Publication number: 20130040979
    Abstract: The invention relates to the use of inhibitors of CCR1 for the treatment of cancers and osteolytic bone disorders. In some embodiments, the invention relates to methods for the treatment of multiple myeloma, smoldering multiple myeloma and secondary bone cancers.
    Type: Application
    Filed: March 19, 2012
    Publication date: February 14, 2013
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Ole Petter Veiby, Kennth C. Anderson, Sonia Vallet
  • Compositions, kits, and methods for identification, assessment, prevention and therapy of breast and ovarian cancer
    Patent number: 8323906
    Abstract: The invention relates to newly discovered nucleic acid molecules and proteins associated with breast or ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast or ovarian cancers are provided.
    Type: Grant
    Filed: December 17, 2008
    Date of Patent: December 4, 2012
    Assignees: Millennium Pharmaceuticals, Inc., Board of Regents, The University of Texas System
    Inventors: Ole Petter Veiby, Robert C. Bast, Jr., Gordon B. Mills, Gabriel N. Hortobagyi
  • Antibodies that bind OV064 and methods of use therefor
    Patent number: 8323645
    Abstract: Antibodies and antigen-binding fragments of antibodies that bind OV064 are disclosed. The antibodies bind an extracellular domain of OV064. Some of the antibodies and antigen-binding fragments bind an epitope on OV064 sufficient to induce internalization. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.
    Type: Grant
    Filed: March 10, 2006
    Date of Patent: December 4, 2012
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Ole Petter Veiby, John S. Babcook
  • Compositions, kits, and methods for identification, assessment, prevention and therapy of breast and ovarian cancer
    Publication number: 20100003682
    Abstract: The invention relates to newly discovered nucleic acid molecules and proteins associated with breast or ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast or ovarian cancers are provided.
    Type: Application
    Filed: December 17, 2008
    Publication date: January 7, 2010
    Applicants: Millennium Pharmaceuticals, Inc., Board of Regents, The University of Texas System
    Inventors: Ole Petter Veiby, Robert C. Bast, JR., Gordon B. Mills, Gabriel N. Hortobagyi
  • CCR1 Inhibitors useful for the treatment of multiple myeloma and other disorders
    Publication number: 20090286823
    Abstract: The invention relates to the use of inhibitors of CCR1 for the treatment of cancers and osteolytic bone disorders. In some embodiments, the invention relates to methods for the treatment of multiple myeloma, smoldering multiple myeloma and secondary bone cancers.
    Type: Application
    Filed: December 17, 2008
    Publication date: November 19, 2009
    Applicant: Millennium Pharmaceuticals Inc.
    Inventors: Ole Petter Veiby, Kenneth C. Anderson, Sonia Vallet
  • Antibodies That Bind OV064 and Methods of Use Therefor
    Publication number: 20090208489
    Abstract: Antibodies and antigen-binding fragments of antibodies that bind OV064 are disclosed. The antibodies bind an extracellular domain of OV064. Some of the antibodies and antigen-binding fragments bind an epitope on OV064 sufficient to induce internalization. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.
    Type: Application
    Filed: March 10, 2006
    Publication date: August 20, 2009
    Applicants: Millennium Pharmaceuticals, Inc. Intellectual Property Group, Amgen, Inc.
    Inventors: Ole Petter Veiby, John S. Babcook
  • Compositions, kits, and methods for identification, assessment, prevention and therapy of breast and ovarian cancer
    Patent number: 7494775
    Abstract: The invention relates to newly discovered nucleic acid molecules and proteins associated with breast or ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast or ovarian cancers are provided.
    Type: Grant
    Filed: March 11, 2005
    Date of Patent: February 24, 2009
    Assignees: Millennium Pharmaceuticals, Inc., UT Board of Regents
    Inventors: Ole Petter Veiby, Robert C. Bast, Jr., Gordon B. Mills, Gabriel N. Hortobagyi
  • Compositions, kits and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
    Publication number: 20030068636
    Abstract: The invention relates to newly discovered nucleic acid molecules and proteins associated with breast or ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast or ovarian cancers are provided.
    Type: Application
    Filed: June 21, 2002
    Publication date: April 10, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventor: Ole Petter Veiby